Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Biopharma Business Development Clinical trials
Five lessons learned deploying agentic AI in the life sciences Five lessons learned deploying agentic AI in the life sciences
Blog April 30, 2026
Five lessons learned deploying agentic AI in the life sciences
AI
Target selection and safety assessment: Navigating early decisions that shape drug development Target selection and safety assessment: Navigating early decisions that shape drug development
Blog March 27, 2026
Target selection and safety assessment: Navigating early decisions that shape drug development
Development Pharma Regulatory
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
Blog March 26, 2026
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
GLP-1 Metabolic
Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Gerontology
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Biotech Clinical trials
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
FDA Regulatory Safety

Biopharma

Biotech financing’s rebound: How high will it go? Biotech financing’s rebound: How high will it go?
Blog September 17, 2024
Biotech financing’s rebound: How high will it go?
Early diagnosis in Alzheimer’s disease: A first step towards better care Early diagnosis in Alzheimer’s disease: A first step towards better care
Blog September 11, 2024
Early diagnosis in Alzheimer’s disease: A first step towards better care
After loss of exclusivity, small-molecule generics bite quick and hard, while biologics remain resilient After loss of exclusivity, small-molecule generics bite quick and hard, while biologics remain resilient
Blog August 28, 2024
After loss of exclusivity, small-molecule generics bite quick and hard, while biologics remain resilient
CMS enters drug price negotiation arena in sea change for industry CMS enters drug price negotiation arena in sea change for industry
Blog August 20, 2024
CMS enters drug price negotiation arena in sea change for industry
Beyond transparent pricing: decoding the strategies of major PBMs Beyond transparent pricing: decoding the strategies of major PBMs
Blog August 7, 2024
Beyond transparent pricing: decoding the strategies of major PBMs
Perceptions of pharmaceutical industry affiliates on the New Active Substance Work-Sharing Initiative of the Access Consortium Perceptions of pharmaceutical industry affiliates on the New Active Substance Work-Sharing Initiative of the Access Consortium
Blog July 8, 2024
Perceptions of pharmaceutical industry affiliates on the New Active Substance Work-Sharing Initiative of the Access Consortium
These seven ADC makers are developing therapies that show promise for hard-to-treat cancers These seven ADC makers are developing therapies that show promise for hard-to-treat cancers
Blog June 17, 2024
These seven ADC makers are developing therapies that show promise for hard-to-treat cancers
Indication Expansion: Pioneering new uses for existing cancer drugs Indication Expansion: Pioneering new uses for existing cancer drugs
Blog May 31, 2024
Indication Expansion: Pioneering new uses for existing cancer drugs
Beyond overall survival: Time to agree on the value of alternative oncology endpoints? Beyond overall survival: Time to agree on the value of alternative oncology endpoints?
Blog May 21, 2024
Beyond overall survival: Time to agree on the value of alternative oncology endpoints?
What a string of semaglutide biosimilars could mean for Mainland China What a string of semaglutide biosimilars could mean for Mainland China
Blog May 14, 2024
What a string of semaglutide biosimilars could mean for Mainland China